Emmaus Life SciencesEMMA -7.26% Receivables Turnover is 0.82 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 841 Biotechnology companies, Emmaus Life Sciences ranks worse than 50.89% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Emmaus Life Sciences's Revenue for the
three
months ended in Mar. 2026 was $1.98 Mil. Emmaus Life Sciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.43 Mil.
Hence, Emmaus Life Sciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.82.
Emmaus Life Sciences (OTCPK:EMMA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Emmaus Life Sciences Receivables Turnover Related Terms
Emmaus Life Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PTIX, BZYR, RMTG: Receivables Turnover Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Receivables Turnover of 0.82 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #428 out of 841 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Emmaus Life Sciences' Receivables Turnover too high?
Emmaus Life Sciences' current Receivables Turnover is 0.82. The Biotechnology industry median Receivables Turnover is 5.27. Emmaus Life Sciences' value of 0.82 is 84.4% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #428 out of 841 companies in the Biotechnology industry, which is below the industry midpoint.
How does Emmaus Life Sciences' Receivables Turnover compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #428 out of 841 companies for Receivables Turnover. This places Emmaus Life Sciences in the lower half of its industry. The industry median Receivables Turnover is 5.27. Emmaus Life Sciences' value of 0.82 is 84.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Receivables Turnover of 0.82 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Receivables Turnover is 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 8.5% above its estimated fair value. The current Receivables Turnover is 0.82 and 84.4% below the Biotechnology industry median of 5.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Receivables Turnover is 0.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 